Fw: Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth.

----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Thursday, February 14, 2008 10:43:25 PM
Subject: Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth.

[1]Anticancer Res. 2007 Nov-Dec; 27(6B): 4239-42
Uematsu K, Seki N, Seto T, Isoe C, Tsukamoto H, Mikami I, You L, He B, Xu Z, Jablons DM, Eguchi K

BACKGROUND: We have previously found that Wnt signaling is activated in mesothelioma cells. To clarify the effect of blocking Wnt signaling in mesothelioma, the expression of dishevelled (Dvl), an intermediator of Wnt signaling, was down-regulated by a reformed type of small interfering RNA (siRNA), stealth RNAi, which can reduce the cytotoxic interferon response unlike conventional siRNA. MATERIALS AND METHODS: Mesothelioma cell lines were transfected with stealth RNAi of Dvl, and cell growth and colony formation were examined. The synergistic effect on cell growth of Dvl stealth RNAi and cisplatin in combination was evaluated. RESULTS: Dvl stealth RNAi down-regulated the expression of Dvl-3 in mesothelioma cells and induced cell cycle aberration which caused suppression of cell growth. Colony formation was also suppressed. Dvl stealth RNAi and cisplatin in combination suppressed cell growth synergistically. CONCLUSION: Our data suggest that inhibition of Wnt signaling leads to significant antitumor effects.



___
Source: http://www.hubmed.org/display.cgi?uids=18225596
--
 

---

Never miss a thing. Make Yahoo your homepage.

Fwd: State pollution board to study Bay cleanup plan

---------- Forwarded message ----------
From: Live Search News: asbestos cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:06 PM
Subject: State pollution board to study Bay cleanup plan
To: mesothelioma77@gmail.com


Oakland Tribune - ... caulking in building materials until their manufacture was banned some 30 years ago because of health concerns about cancer ... Will PCBs be the next asbestos?" Mumley asked. "We don't know." In another test, cities and counties will jointly study five ...

Wed, 13 Feb 2008 10:48:00 GMT

___
Source: http://www.insidebayarea.com/oaklandtribune/ci_8248603
--
 

Fwd: Mutant enzyme linked to deadliest cancers

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:07 PM
Subject: Mutant enzyme linked to deadliest cancers
To: mesothelioma77@gmail.com

Scientists have captured an image of an enzyme key to the progression of the deadliest cancers and said on Wednesday their findings may lead to new therapies against not only cancer, but HIV and diabetes too.

Fri, 15 Feb 2008 02:37:05 GMT

---

Source: http://www.freerepublic.com/focus/f-news/1970646/posts
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Veterans Organizations Call for Lung Cancer Screening (PR Newswire via Yahoo! News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:07 PM
Subject: Veterans Organizations Call for Lung Cancer Screening (PR Newswire via Yahoo! News)
To: mesothelioma77@gmail.com

Today, Lung Cancer Alliance announced that for the second year in row, a coalition of top veteran organizations called for a screening program for veterans at high risk of lung cancer.

Thu, 14 Feb 2008 20:50:00 GMT

___

Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=1371fbkpd/*http%3A//news.yahoo.com/s/usnw/20080214/pl_usnw/veterans_organizations_call_for_lung_cancer_screening

--
 

Fwd: Estimation of BCL-2 protein in carcinoma of the breast and its clinical correlation in locally advanced breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:07 PM
Subject: Estimation of BCL-2 protein in carcinoma of the breast and its clinical correlation in locally advanced breast cancer.
To: mesothelioma77@gmail.com


[1]J Cancer Res Ther. 2007 Oct-Dec; 3(4): 207-10
Aggarwal H, Lubana PS, Jain DK, Mathur RK

The change in expression of apoptotic markers (Bcl-2 and Bax proteins) brought about by various chemotherapeutic regimens is being used for its predictive value for assessing response to neoadjuvant chemotherapy (NACT) in locally advanced breast carcinoma (LABC). AIMS: (1) Estimation of Bcl 2 expression in LABC, (2) Any change in Bcl 2 expression following chemotherapy in LABC, (3) Any relation of Bcl 2 estimation to changes in size of tumor, nodal status, age, and menopausal status. SETTINGS AND DESIGN: This was a prospective study of 120 cases of LABC. MATERIALS AND METHODS: All cases were subjected to biopsy and the tissue was evaluated immunohistochemically for apoptotic marker Bcl-2 family protein. Three cycles of NACT were given at three-weekly intervals. Modified radical mastectomy was performed and the specimens were re-evaluated for any change in the Bcl-2 family protein. The clinical response and immunohistochemical response were correlated and compared. STATISTICAL ANALYSIS: Coefficient of correlation was calculated by Pearson correlation coefficient (P-value). RESULTS: Clinical response, as measured by reduction in the tumor size, was observed in 81 (67.5%) patients while immunohistochemical response was observed in 67 (55.8%) patients. Correlation between immunohistochemical and clinical response was found to be statistically significant (P = 0.02). Nodal response was seen in 72 (60%) patients. There were no patients in the N o group; 22 (53.7%) of the N 1 patients were down-staged to N o , while 19 (46.3%) remained N 1 . In patients with N 2 disease, 11 (13.9%) were down-staged to N o status, 39 (49.4%) were down-staged to N 1 status, and 29 (36.7%) did not show any response. Immunohistochemical response was observed in 67 (55.8%) patients. Correlation between immunohistochemical and nodal responses was also found to be statistically significant (P = 0.03). CONCLUSIONS: This significant positive correlation between clinical and immunohistochemical responses highlights the importance of apoptotic marker Bcl-2 family protein in predicting the response of LABC to NACT.



___
Source: http://www.hubmed.org/display.cgi?uids=18270395
--
 

Fwd: Colorectal cancer care knowledge mapping: identifying priorities for knowledge translation research.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:06 PM
Subject: Colorectal cancer care knowledge mapping: identifying priorities for knowledge translation research.
To: mesothelioma77@gmail.com


[1]Cancer Causes Control. 2008 Feb 13;
Gagliardi AR, Wright FC, Grunfeld E, Davis D

OBJECTIVE: We do not know the extent and nature of knowledge translation (KT) in oncology. This study examined colorectal cancer (CRC) health services research, and engaged researchers and decision makers in prioritizing KT research gaps. METHODS: MEDLINE was searched from 1996 to 2006 for CRC health services research in Canada, Australia, the United Kingdom, and United States. Studies were tabulated by indicator, type of research and country to reveal gaps. Researchers and decision makers prioritized gaps via questionnaire, then generated research questions for top-ranked gaps at a one-day workshop. RESULTS: A total of 132 articles were categorized and 29 individuals attended the workshop. We lack knowledge about factors influencing rates of many indicators. Researchers and decision makers prioritized KT research on factors that could either influence the utilization of screening or enhance the quality of surgical outcomes. They acknowledged lack of research capacity and policy support as barriers, and confusion about the concept of KT. CONCLUSIONS: Several opportunities were revealed for improving the quality of CRC screening and surgery. Greater coordination of, and support for KT research is required to address these gaps. Further research should evaluate different methods of achieving KT between researchers and decision makers for research planning.



___
Source: http://www.hubmed.org/display.cgi?uids=18270797
--
 

Fwd: A new method to evaluate the completeness of case ascertainment by a cancer registry.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:06 PM
Subject: A new method to evaluate the completeness of case ascertainment by a cancer registry.
To: mesothelioma77@gmail.com


[1]Cancer Causes Control. 2008 Feb 13;
Das B, Clegg LX, Feuer EJ, Pickle LW

BACKGROUND: Epidemiologic research into cancer and subsequent decision making to reduce the cancer burden in the population are dependent on the quality of available data. The more reliable the data, the more confident we can be that the decisions made would have the desired effect in the population. The North American Association of Central Cancer Registries (NAACCR) certifies population-based cancer registries, ensuring uniformity of data quality. An important assessment of registry quality is provided by the index of completeness of cancer case ascertainment. NAACCR currently computes this index assuming that the ratio of cancer incidence rates to cancer mortality rates is constant across geographic areas within cancer site, gender, and race groups. NAACCR does not incorporate the variability of this index into the certification process. METHODS: We propose an improved method for calculating this index based on a statistical model developed at the National Cancer Institute to predict expected incidence using demographic and lifestyle data. We calculate the variance of our index using statistical approximation. RESULTS: We use the incidence model to predict the number of new incident cases in each registry area, based on all available registry data. Then we adjust the registry-specific expected numbers for reporting delay and data corrections. The proposed completeness index is the ratio of the observed number to the adjusted prediction for each registry. We calculate the variance of the new index and propose a simple method of incorporating this variability into the certification process. CONCLUSIONS: Better modeling reduces the number of registries with unrealistically high completeness indices. We provide a fuller picture of registry performance by incorporating variability into the certification process.



___
Source: http://www.hubmed.org/display.cgi?uids=18270798
--
 

Fwd: [The Physical, Psychological, Social, and Spiritual Impacts of Malignant Fungating Wounds on Cancer Patients.]

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:06 PM
Subject: [The Physical, Psychological, Social, and Spiritual Impacts of Malignant Fungating Wounds on Cancer Patients.]
To: mesothelioma77@gmail.com


[1]Hu Li Za Zhi. 2008 Feb; 55(1): 75-80
Lo SF, Hu WY

Malignant fungating wounds (MFW) are accompanied by odor, secretions, bleeding and pain. Cancer patients must not only suffer the physical, psychological, social and spiritual impacts on their disease, but also experience considerable change in health-related quality of life. Palliative health care aims to provide comprehensive services to patients and their families. To date, no study has adopted the standpoint of palliative health care to describe comprehensively the impacts of MFWs on cancer patients, with the result that health professionals are incapable of providing comprehensive care to such patients. This study illustrates the etiology of MFWs, their physical, psychological, social, and spiritual impacts on cancer patients, and wound care strategies. It aims to improve nurses' knowledge and understanding of how to assess and identify the etiology of MFWs, in the hope that such knowledge can be applied in clinical practice and as a reference for nurses organizing MFW plans, in order to provide better patient care.



___
Source: http://www.hubmed.org/display.cgi?uids=18270936
--
 

Fwd: Initial tumor size predicts histologic response and survival in localized osteosarcoma patients.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:06 PM
Subject: Initial tumor size predicts histologic response and survival in localized osteosarcoma patients.
To: mesothelioma77@gmail.com


[1]J Surg Oncol. 2008 Feb 12;
Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jeon DG

BACKGROUND: To evaluate the correlation between histologic response and size parameters, and to analyze the prognostic importance of size parameters on metastasis-free survival in localized osteosarcoma patients. METHODS: We retrospectively reviewed 331 patients with stage II osteosarcoma treated with surgery and chemotherapy. The tumor size parameters were measured and calculated based on MR images. The mean metastasis-free interval was 77.8 months (range, 3-205 months; median, 67 months). RESULTS: Tumor size is best defined by relative tumor plane (RTP). Patients with a large tumor (RTP>27.5 cm(2)/m(2)) had a significant correlation with poor histologic response and distal femoral tumor location. The independent prognostic factors for metastasis-free survival were American Joint Committee on Cancer (AJCC) stage, RTP, proximal humerus location, chondroblastic subtype, and poor histologic response. CONCLUSION: The initial tumor size is closely related to histologic response and is an important prognostic factor in osteosarcoma. Tumor size is best represented by AJCC stage and RTP. These parameters may serve as a basis for risk-adapted therapy in combined stratification with histologic response. J. surg. Oncol. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18270971
--
 

Fwd: P53 Overexpression in Bladder Urothelial Neoplasms: New Aspect of World Health Organization/International Society of Urological Pathology Classification.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:06 PM
Subject: P53 Overexpression in Bladder Urothelial Neoplasms: New Aspect of World Health Organization/International Society of Urological Pathology Classification.
To: mesothelioma77@gmail.com


[1]Urol J. 2007; 4(4): 230-233
Kalantari MR, Ahmadnia H

INTRODUCTION: The aim of this study was to investigate the probable differences in P53 expression between papillary urothelial neoplasm of low malignant potential (PUNLMP) and varying grades of transitional cell carcinoma (TCC) of the bladder. MATERIALS AND METHODS: Ten biopsy specimens of the patients with PUNLMP, 20 of the patients with papillary low-grade TCC, 20 of those with invasive high-grade TCC, and 10 of healthy individuals were stained for P53 protein by immunohitochemical methods. Histological grading was performed according to the World Health Organization/International Society of Urological Pathology consensus classification of urothelial neoplasms of the urinary bladder. RESULTS: Nuclear P53 protein in invasive high-grade TCC was slightly more frequent than that in noninvasive low-grade papillary TCC (P = .35). Ten percent of specimens with PUNLMP had nuclear P53 accumulation, while in low-grade and high-grade TCCs, 75% and 85% of the specimens were positive for P53 protein accumulation (P

___
Source: http://www.hubmed.org/display.cgi?uids=18270948
--
 

Fwd: TGF-beta signalling-related markers in cancer patients with bone metastasis.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:06 PM
Subject: TGF-beta signalling-related markers in cancer patients with bone metastasis.
To: mesothelioma77@gmail.com


[1]Biomarkers. 2008 Mar; 13(2): 217-236
Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, Carducci M

We measured transforming growth factor (TGF)-beta-dependent biomarkers in plasma and in peripheral blood mononuclear cells (PBMCs) to identify suitable pharmacodynamic markers for future clinical trials with TGF-beta inhibitors. Forty-nine patients with bone metastasis were enrolled in the study, including patients with breast (n=23) and prostate cancer (n=15). Plasma TGF-beta1 levels were elevated in more than half of the cancer patients (geometric mean 2.63 ng ml(-1)) and positively correlated with increased platelet factor 4 (PF4) levels, parathyroid-related protein (PTHrP), von Willebrand Factor (vWF) and interleukin (IL)-10. PBMC were stimulated ex vivo to determine the individual biological variability of an ex vivo assay measuring pSMAD expression. This assay performed sufficiently well to allow its future use in a clinical trial of a TGF-beta inhibitor.



___
Source: http://www.hubmed.org/display.cgi?uids=18270872
--